Agilent Technologies Engager | In-Person Event

agilent tech

Tuesday 15th November, 2022 | 6.00pm - 8:00pm ET

Boston, MA

The Role of Liquid Biopsy in Enabling Development of Biomarker-Driven Targeted Therapies

Liquid biopsy-based cfDNA diagnostics are continuing to become an integral part of a patient’s journey. From early detection, clinical diagnosis, therapy selection, resistance detection and response and relapse monitoring.

The Agilent Technologies Engager will be focusing on the utilization of liquid biopsies in therapy selection, detection of biomarkers that cause resistance and continued response monitoring and how this can be used to advance novel biomarker discovery.

Exclusively designed for Biopharma Directors, Heads & VPs working in the liquid biopsy, companion diagnostics and clinical development space, this 2-hour networking event will be addressing how liquid biopsy-based cfDNA diagnostics are currently being applied from discovery all the way through to companion diagnostic development, and how they can lead to the advancement of additional combinational therapies as well as novel biomarkers for therapeutic development.

This is your opportunity to gain insights from industry leading experts from diagnostic development, therapeutic development, and academic research!

With an insightful panel discussion among key opinion leaders followed by complimentary appetizers and drinks, this is a date not to be missed!

Your Expert Speakers:

Reserve Your Free Seat By Filling Out the Form Below:

Please Note: This event is taking place in-person only (Boston, MA) and online attendance will not be available.

This event is reserved for decision makers and senior representatives in the biopharma community with therapies in their pipeline. By registering online, you are submitting your interest in this exclusive networking meeting, and a colleague will be in touch upon registering to confirm or decline your place based on the mentioned criteria.

Having trouble registering? Email: info@hansonwade.com

*Attendance is subject to final approval from the event organizers

Agenda

6:00 pm Registration & Welcome Reception

6:30 pm Opening Remarks & Introduction

  • John Palma Vice President, Head of Global Medical Affairs, Agilent Technologies

6:35 pm Panel Discussion & Q&A: The Role of Liquid Biopsy in Enabling Development of Biomarker-driven Targeted Therapies

  • John Palma Vice President, Head of Global Medical Affairs, Agilent Technologies
  • Kenna Anderes Vice President, Translational Medicine & Companion Diagnostics, Mirati Therapeutics
  • Cloud Paweletz Head of Research at Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute

Synopsis

  • Evolving landscape of biomarker testing across tumour types
  • Discovering actionable mechanisms of resistance in liquid biopsy
  • Leveraging continued advances in liquid biopsy’s accessibility and accuracy to advance novel biomarker disco

7:20 pm Networking Session

Synopsis

This is an informal and exclusive networking opportunity for you to engage with biopharma leaders to discuss how to advance the Liquid Biopsy space!

8:00 pm End of Agilent Technologies Engager

About Agilent Technologies:

agilent tech

Agilent Technologies is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions.

By partnering with Agilent for your CDx development, your drug development program will reap the benefits of an innovative industry leader with more than 20 years’ experience. Agilent launched the first FDA-approved companion diagnostic and continues to deliver world-class CDx products in close collaboration with our pharma partners

www.agilent.com